{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000014","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.874595+00:00","generated_at":"2026-06-07T03:53:19.732239+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aldeyra advances RASP modulator pipeline; multiple IND submissions and trial initiations planned for 2024","bullets":["Positive biomarker results from ADX-629 in Sjögren-Larsson Syndrome adult cohort; pediatric expansion submission expected H1 2024.","Phase 2 trial of ADX-629 in moderate alcoholic hepatitis initiated; top-line results expected H2 2024.","IND for ADX-246 submitted for phase 1 in healthy volunteers; expected to expand to atopic dermatitis patients; top-line results H2 2024.","IND for ADX-248 expected in 2024 for phase 1/2 in dry AMD with dark adaptation deficit.","De-prioritized ADX-629 in chronic cough and idiopathic nephrotic syndrome; new preclinical RASP modulator program in metabolic disease initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000014","json":"https://secwatch.observer/filing/0001157523-24-000014.json","markdown":"https://secwatch.observer/filing/0001157523-24-000014.md","text":"https://secwatch.observer/filing/0001157523-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/0001157523-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752324000014/a53876982.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:53:19.732239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}